title: Does cilengitide deserve another chance?-Authors' reply.
authors.affiliation: University Hospital Zurich, 8006 Zurich, Switzerland; European Organisation for Research and Treatment of Cancer, Brussels, Belgium. Electronic address: Roger.Stupp@usz.ch.
authors.forename: Roger
authors.initials: R
authors.lastname: Stupp
authors.affiliation: Merck KGaA, Darmstadt, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Picard
authors.affiliation: University Hospital Zurich, 8006 Zurich, Switzerland; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy*; D015254:DNA Modification Methylases / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000235:genetics*; D003606:Dacarbazine / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012910:Snake Venoms / Q000627:therapeutic use*; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D012910:Snake Venoms; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; D045643:DNA Repair Enzymes